FREMONT, Calif., Aug. 2, 2017 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a late-stage clinical company focused on enhancing
the treatment of patients with cardiorenal and gastrointestinal
(GI) diseases, today announced that management will host a
conference call in conjunction with its second quarter 2017
financial results and present at the 2017 Wedbush PacGrow
Healthcare Conference. Details of both events are as follows:
- Second Quarter 2017 Financial Results: Management will
host a conference call and webcast on Wednesday, August 9, 2017, at 8:00 a.m. ET to provide a business update and
review second quarter 2017 financial results. To participate in the
conference call, please dial (855) 296-9612 (domestic) or (920)
663-6277 (international) and refer to conference ID 47784045. The
webcast can be accessed under "Events and Presentations" in the
investor section of the company's website at www.ardelyx.com.
- Wedbush PacGrow Healthcare Conference Presentation:
Management will present a company overview at the 2017 Wedbush
PacGrow Healthcare Conference on Wednesday,
August 16, 2017 at 2:30 p.m.
ET in New York City. A live
webcast of the presentation can be accessed under "Events and
Presentations" in the investor section of the company's website at
www.ardelyx.com.
Replays of both webcasts will be available in the investor
section of the company's website for 60 days following the call and
presentation.
About Ardelyx, Inc.
Ardelyx is focused on
enhancing the way patients with cardiorenal and gastrointestinal
(GI) diseases are treated by using the gut as the gateway to
delivering medicines that matter. The company has established
unique cardiorenal and GI business portfolios aimed at bringing
new, effective medicines with distinct safety and dosing advantages
to underserved patients. Ardelyx's cardiorenal portfolio
includes the Phase 3 development of tenapanor for the treatment of
hyperphosphatemia in people with end-stage renal disease who are on
dialysis and the Phase 3 development of RDX7675 for the treatment
of people with hyperkalemia. The company's GI portfolio includes
the Phase 3 development of tenapanor for the treatment of people
with irritable bowel syndrome with constipation (IBS-C), and
RDX8940, a TGR5 agonist approaching Phase 1 development. For more
information, please visit www.ardelyx.com and connect
with us on Twitter @Ardelyx.
View original content with
multimedia:http://www.prnewswire.com/news-releases/ardelyx-announces-date-of-second-quarter-financial-results-and-presentation-at-wedbush-pacgrow-healthcare-conference-300498033.html
SOURCE Ardelyx